Recursion Pharmaceuticals (NASDAQ:RXRX) outlined progress across its clinical pipeline, drug-discovery partnerships and ...
Recursion Pharmaceuticals, Inc. (RXRX), the self-styled "clinical-stage TechBio company with a mission to decode biology to radically improve lives" (Source: 2025 annual report/10-K filing), reported ...
Bullish option flow detected in Recursion Pharmaceuticals (RXRX) with 35,100 calls trading, 5x expected, and implied vol increasing almost 42 points to 161.96%. 10/24 weekly 7 calls and 10/24 weekly 7 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results